Regional Variation in Aortic AT1b Receptor mRNA Abundance Is Associated with Contractility but Unrelated to Atherosclerosis and Aortic Aneurysms by Poduri, Aruna et al.
University of Kentucky
UKnowledge
Pharmacology and Nutritional Sciences Faculty
Publications Pharmacology and Nutritional Sciences
10-31-2012
Regional Variation in Aortic AT1b Receptor
mRNA Abundance Is Associated with
Contractility but Unrelated to Atherosclerosis and
Aortic Aneurysms
Aruna Poduri
University of Kentucky, aruna.poduri@uky.edu
A. Phillip Owens
University of Kentucky, phillip.owens@uky.edu
Deborah A. Howatt
University of Kentucky, deborah.howatt@uky.edu
Jessica J. Moorleghen
University of Kentucky, jjmoorl@uky.edu
Anju Balakrishnan
University of Kentucky, abala3@uky.edu
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/pharmacol_facpub
Part of the Cardiology Commons
This Article is brought to you for free and open access by the Pharmacology and Nutritional Sciences at UKnowledge. It has been accepted for inclusion
in Pharmacology and Nutritional Sciences Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Poduri, Aruna; Owens, A. Phillip; Howatt, Deborah A.; Moorleghen, Jessica J.; Balakrishnan, Anju; Cassis, Lisa A.; and Daugherty,
Alan, "Regional Variation in Aortic AT1b Receptor mRNA Abundance Is Associated with Contractility but Unrelated to
Atherosclerosis and Aortic Aneurysms" (2012). Pharmacology and Nutritional Sciences Faculty Publications. 4.
https://uknowledge.uky.edu/pharmacol_facpub/4
Authors
Aruna Poduri, A. Phillip Owens, Deborah A. Howatt, Jessica J. Moorleghen, Anju Balakrishnan, Lisa A.
Cassis, and Alan Daugherty
Regional Variation in Aortic AT1b Receptor mRNA Abundance Is Associated with Contractility but Unrelated to
Atherosclerosis and Aortic Aneurysms
Notes/Citation Information
Published in PLoS One, v. 7, no. 10, p. 48462.
© 2012 Poduri et al. This is an open-access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Digital Object Identifier (DOI)
http://dx.doi.org/10.1371/journal.pone.0048462
This article is available at UKnowledge: https://uknowledge.uky.edu/pharmacol_facpub/4
Regional Variation in Aortic AT1b Receptor mRNA
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Abstract
Background: Angiotensin II (AngII), the main bioactive peptide of the renin angiotensin system, exerts most of its biological
actions through stimulation of AngII type 1 (AT1) receptors. This receptor is expressed as 2 structurally similar subtypes in
rodents, termed AT1a and AT1b. Although AT1a receptors have been studied comprehensively, roles of AT1b receptors in
the aorta have not been defined.
Methodology/Results: We initially compared the regional distribution of AT1b receptor mRNA with AT1a receptor mRNA in
the aorta. mRNA abundance of both subtypes increased from the proximal to the distal aorta, with the greatest abundance
in the infra-renal region. Corresponding to the high mRNA abundance for both receptors, only aortic rings from the infra-
renal aorta contracted in response to AngII stimulation. Despite the presence of both receptor transcripts, deletion of AT1b
receptors, but not AT1a receptors, diminished AngII-induced contractility. To determine whether absence of AT1b receptors
influenced aortic pathologies, we bred AT1b receptor deficient mice into an LDL receptor deficient background. Mice were
fed a diet enriched in saturated fat and infused with AngII (1,000 ng/kg/min). Parameters that could influence development
of aortic pathologies, including systolic blood pressure and plasma cholesterol concentrations, were not impacted by AT1b
receptor deficiency. Absence of AT1b receptors also had no effect on size of aortic atherosclerotic lesions and aortic
aneurysms in both the ascending and abdominal regions.
Conclusions/Significance: Regional abundance of AT1b receptor mRNA coincided with AngII-induced regional contractility,
but it was not associated with AngII-induced aortic pathologies.
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Introduction
Angiotensin II (AngII) is the major effector of the renin
angiotensin system that exerts its actions predominantly through
stimulation of AT1 receptors [1–3]. In rodents, this receptor
undergoes chromosomal duplication and is expressed as two
subtypes, named AngII type 1a (AT1a) and type 1b (AT1b)
receptors [4]. These two receptor subtypes are present on different
chromosomes, 13 and 3 for AT1a and AT1b in mice, respectively.
While AT1a receptors have ubiquitous tissue expression, AT1b
receptor expression is more restricted to tissues such as aorta,
resistance arteries, adrenal glands, pituitary, and hypothalamus
[2,5–8]. The aorta is one of the few tissues that express both
subtypes, presumably in medial smooth muscle cells (SMCs) [2].
AT1 receptor subtypes in rodents are highly homologous, both
containing 359 amino acids that have 94% similarity [9,10]. AngII
stimulation of both subtypes are inhibited indiscriminately by the
sartan class of pharmacological inhibitors [9,10]. However, the
consequences of AngII stimulation of the two subtypes could vary
in the same cell type as several of the amino acid differences
between the two subtypes are clustered in the intracellular domain
of the third loop and the cytoplasmic tail. Despite not being
characterized yet, amino acid substitutions in these structural
positions have the potential to impart differences on multiple
signaling pathways that are invoked by AngII stimulation of AT1
receptors [1].
AngII provokes region-specific effects on the aorta. Ex vivo, this
heterogeneity is reflected by differences in AngII promoting aortic
contractility with only the abdominal region being responsive
[2,3,11]. Recently, it has been demonstrated that aortic contrac-
tion induced by AngII is restricted to the infra-renal region of the
abdominal aorta [3]. However, it is unclear whether this region-
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specific effect is related to the relative abundance of the receptor
subtypes along the length of the aorta.
AngII infusion augments atherosclerosis in hypercholesterol-
emic mice [12,13]. AngII infusion also promotes aortic aneurysms
in both the ascending and supra-renal regions, which represent
two distinct pathologies [12,14]. Whole body AT1a receptor
deficiency attenuates atherosclerosis and aortic aneurysms in mice
infused with AngII [3,15]. In contrast to AT1a receptors, AT1b
receptors regulate calcium signaling in vascular smooth muscle
cells of the aorta and blood pressure in response to AngII
stimulation [16,17], indicating a potentially important role of
AT1b receptors in vascular diseases. Although AT1b receptors are
also an AngII binding receptor that is abundant in the aorta, it has
not been determined whether this receptor subtype also influences
atherosclerosis and aortic aneurysms in mice infused with AngII.
AT1b receptor mRNA has been detected in the aorta [2].
However, no study has reported whether there are regional
differences of AT1b receptor mRNA in the aorta. In the present
study, we initially quantified the mRNA abundance of AT1a and
AT1b receptors in distinct aortic regions. Both subtypes were
primarily expressed in the infra-renal aortic region. Despite the
presence of transcripts for both receptors in this region, deletion of
AT1b receptors, but not deletion of AT1a receptors, inhibited
AngII-induced contractility. In contrast to the major role of AT1a
receptors, deletion of the AT1b receptor subtype had no effect on
AngII-induced atherosclerosis and aortic aneurysms.
Materials and Methods
Ethics Statement
All mouse studies were performed with approval of the
University of Kentucky Institutional Animal Care and Use
Committee (IACUC number: 2006-0009). Pump implantation
was conducted using isoflurane inhalation anesthesia, and
termination was performed with overdose of ketamine/xylazine.
All efforts were taken to minimize suffering to mice in accordance
with the University of Kentucky IACUC and the Care and Use of
Laboratory Animals per the National Institutes of Health
guidelines.
Mice
Male low density lipoprotein (LDL) receptor 2/2 (B6.129S7-
ldlrtm1her; Stock# 002207) and AT1a receptor 2/2 (B6.129P2-
Agtr1atm1Unc; Stock# 002682) mice were obtained from The
Jackson Laboratory (Bar Harbor, ME, USA). AT1b receptor 2/2
mice in a C57BL/6 background were generated at Duke
University (Durham, NC, USA) and were a generous gift from
Dr. Thomas Coffman [18]. All mice were backcrossed 10 times
into a C57BL/6 background. Male AT1b receptor 2/2 mice
were mated to female LDL receptor 2/2 mice to generate
heterogeneous progeny. The F2 progeny were screened for
developing breeding pairs of AT1b receptor +/+ or 2/26LDL
receptor 2/2 mice. AT1b receptor +/+ and 2/2 mice in the
LDL receptor 2/2 background were used for the present study.
Mice were maintained in a barrier facility and fed a standard
laboratory diet unless specified otherwise.
Real-time PCR
RNA was isolated from aortic tissues of C57BL/6 mice by
RNeasy fibrous tissue kit (Cat# 74704, Qiagen, Valenica, CA,
USA). RNA was reversely transcribed using an iScript cDNA
synthesis kit (Cat# 170–8891, Bio-Rad, Hercules, CA, USA). Real
time PCR was performed using a CFX96 cycler (Bio-Rad).
Taqman probes (ABI, Carlsbad, CA, USA) specific for AT1a and
AT1b receptors, respectively, were used to measure mRNA
abundance. mRNA abundance in the selected aortic regions was
calculated with 18S rRNA normalization using the DDCt method.
Samples containing either no template or no RT reactions were
used as negative controls.
Genotyping
DNA was isolated from tail tissues using a DNeasy blood and
tissue kit (Cat# AS1120, Promega, Madison, WI, USA). Mouse
genotypes were determined by polymerase chain reaction (PCR).
AT1b receptor genotyping was determined using the following
primers: 59-GCATCATCTTTGTGGTGGG and 59-ATGAG-
CACATCCAGAAAA C. The PCR was performed with 1 step of
94uC for 5 min; 35 cycles of 94uC for 1 min, 55uC for 1 min, and
72uC for 2 min; and 1 step of 72uC for 5 min. Wild type and
disrupted alleles generated amplicon sizes of 550 bp and 1,600 bp,
respectively. AT1a receptor and LDL receptor genotypes were
verified by PCR as described previously [19].
Aortic Contractility
Mice were anesthetized with ketamine (100 mg/kg) and
xylazine (10 mg/kg) as described previously [20]. Aortas from
C57BL/6, AT1a receptor 2/2, and AT1b receptor 2/2 mice
were perfused with saline via the left ventricle and then removed,
and adventitia were cleaned off completely without damages of the
media portion. Measurement of contractile activity was performed
using infra-renal aortic rings as described previously [3]. Infra-
renal segments were mounted by passing two tungsten wires
through the arterial lumen and arterial segments were immersed
in Krebs Henseleit solution. Tension (1 gram) was maintained
continuously and recorded with a Micro-Med Tissue Analyzer
(TFA-410, Louisville, KY, USA). After a 30 min equilibration,
tissues were incubated with potassium chloride (KCl; 80 mM,
Sigma, St Louis, MO, USA), 5-hydroxytryptamine (5-HT; 1 mM,
Sigma), or AngII (1 mM, Sigma) for 30 min between the agonists.
Diet and AngII Infusions
To induce hypercholesterolemia, mice were fed a diet
supplemented with saturated fat (milk fat 21% wt/wt) and
cholesterol (0.2% wt/wt; Diet# TD.88137, Harlan Teklad,
Madison, WI, USA) ad libitum starting 1 week prior to pump
implantation, and continuing for the 28 days of saline or AngII
infusion. After 1 week of feeding, AngII (1,000 ng/kg/min; Cat#
H-1705, Bachem, Torrance, CA, USA) was infused subcutane-
ously into 8–10 week old male mice subcutaneously via Alzet
osmotic minipumps (Model 2004, Durect Corporation, Cupertino,
CA, USA) for 28 days as described previously [12,21].
Systolic Blood Pressure Measurements
Systolic blood pressure (SBP) was measured during the last week
for 5 consecutive days of AngII infusion using a non-invasive tail
cuff system (Coda 8, Kent Scientific Corporation, Torrington, CT,
USA) on conscious mice as described previously [22].
Plasma Component Measurements
Blood was drawn by right ventricular puncture and collected in
EDTA (1.8 mg/ml) coated vials at termination. Plasma cholesterol
concentrations were quantified with a commercially available
enzymatic kit (Cat# Cholesterol E 439–17501, Wako Chemical
USA, Richmond, VA, USA) as described previously [23]. Plasma
renin concentrations were measured by radioimmunoassay using a
commercially available kit (Cat# 1553, DiaSorin Inc., Stillwater,
MN, USA) as described previously [20].
AT1b Receptors and Aortic Pathologies
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Atherosclerosis and Aortic Aneurysm Quantification
After exsanguination, saline was perfused through the left
ventricle of the heart. Aortas were removed and kept in neutrally
buffered formalin (10% w/v) overnight before adventitia were
cleaned off completely. Thoracic aorta was cut open and pinned.
Aortic arch region included the ascending aorta, aortic arch, and
3 mm distal from the aortic orifice of the left subclavian artery.
The remaining length of the thoracic aorta till the last intercostal
branches was defined as the descending thoracic aorta. Athero-
sclerosis was quantified on the intima of both the arch and
descending thoracic regions as described previously [24]. Oil Red
O staining of aortas was performed as described previously
[24,25].
Luminal diameters of abdominal aortas were measured in vivo
with a high frequency ultrasound (Vevo 660, VisualSonics,
Toronto, Canada) on day 0 (the day before osmotic minipump
implantation) and day 28 during AngII infusion as described
previously [26]. This system acquired images that were used to
measure maximal lumen dilation. After termination, aortas were
cleaned off adventitia and pinned, and maximal external supra-
renal diameters were measured using Image-Pro Software 7.0
(Media Cybernetics Inc., Bethesda, MD, USA) as described
previously [27].
After measurements of ex vivo diameter, supra-renal aortas
were embedded in optimal cutting temperature compound and
serially sectioned in a cryostat. Tissues were sectioned in a serial
set of 8 slides that contained 9 sections (thickness: 10 mm/section)
of each slide. To characterize AAAs, Movat’s pentachrome
staining was performed as described in our previous studies [28].
Statistical Analyses
SigmaPlot 12.0 (SYSTAT Software Inc., San Jose, CA, USA)
was used for statistical analyses. Data were represented as mean 6
standard error of mean (SEM). Student’s t test or Mann-Whitney
Rank Sum test was performed as appropriate for two-group
comparisons, and one way ANOVA was performed for multiple-
group (more than 2 groups) comparisons. Two way ANOVA with
Holm-Sidak post hoc analysis was performed for multiple-group
and multiple-manipulation analysis. Two way repeated measures
ANOVA was conducted to compare aortic diameters measured on
day 0 and day 28 using ultrasonography. A P,0.05 was
considered statistically significant.
Results
mRNA Abundance of Both AT1 Receptor Subtypes was
Increased in Infra-renal Aortas
We first measured mRNA abundance of both receptor subtypes
throughout the aorta by real-time PCR. mRNA abundance of
receptor subtypes was increased significantly in the infra-renal
aorta compared to other selected regions of aortas (Figure 1A and
1B; P,0.001). Compared to the infra-renal region, mRNA
abundance of both receptor subtypes was much lower in supra-
renal aortas, and very low in both ascending and descending aortic
regions (Figure 1A and 1B). In agreement with previous studies
[2,5,8], we observed higher relative abundance of AT1a receptor
mRNA in liver and kidney, while AT1b receptor mRNA was
either not detected or negligible in these tissues (data not shown).
AT1b Receptor Deficiency Abolished AngII-induced Infra-
renal Contractile Response
Given differences in regional mRNA abundance of both
receptor subtypes along the length of aortic tissue, we sought to
compare the role of these receptor subtypes in AngII-induced
contraction. Previous studies have noted a distinction in AngII-
induced contractility in thoracic and abdominal regions [3], but it
has not been defined whether there were further distinctions
between the receptor subtypes in abdominal aortas. After
confirmation of deletion of AT1a receptor or AT1b receptor
alleles by PCR, we performed contractile studies using aortic rings
from aortas of C57BL/6, AT1a receptor 2/2, and AT1b
receptor 2/2 mice, respectively. As expected, KCl and 5-HT
contracted infra-renal aortic rings in all genotypes (Figure 2). As
reported previously, AngII only contracted rings isolated from the
infra-renal region (Figure 2A) [3]. Furthermore, we confirmed that
deletion of AT1a receptors had no effect on AngII-induced
contractions (Figure 2B) [3]. In contrast, deficiency of AT1b
receptors markedly reduced AngII-induced contraction in the
infra-renal aorta (Figure 2C).
AT1b Receptor Deficiency Had No Effect on AngII-
induced Increases of SBP
A previous study inferred a role of AT1b receptors in blood
pressure regulation [17] and plasma renin concentrations [29].
Following the demonstration of a functional role of AT1b
receptors in aortic tissues, we infused AngII for 28 days into
Figure 1. Region-specific differences in aortic mRNA abun-
dance of AT1a and AT1b receptors. mRNA abundance of (A) AT1a
receptors (N = 4) and (B) AT1b receptors (N = 4) in aortic regions of
C57BL6/J mice. * denotes P,0.05 in supra-renal versus ascending and
descending aortic regions (one way ANOVA with Holm-Sidak post hoc
test). # denotes P,0.001 in the infra-renal region versus all the other
aortic regions (one way ANOVA with Holm-Sidak post hoc test).
doi:10.1371/journal.pone.0048462.g001
AT1b Receptors and Aortic Pathologies
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AT1b receptor +/+ and 2/2 mice. Whole body deficiency of
AT1b receptors during AngII infusion had no significant effect on
body weight and did not change plasma renin concentrations
(Table 1). Deletion of AT1b receptors had no significant effect on
SBP in response to AngII (Table 1).
AT1b Receptor Deficiency Had No Effect on AngII-
induced Aortic Atherosclerosis
In male LDL receptor 2/2 mice that were either AT1b
receptor +/+ or 2/2 were infused with AngII for 28 days. There
was no significant difference in plasma cholesterol concentrations
between the groups (Table 1). Atherosclerotic lesion size was
quantified on the intimal surfaces of the aortic arch and
descending thoracic regions of all mice. Abdominal aortic region
was excluded because the presence of AAAs impedes accurate
measurement of atherosclerosis. There was no significant differ-
ence in percent atherosclerotic lesion area in the aortic arch
(Figure 3A) and descending thoracic regions (Figure 3B) of AT1b
receptor +/+ and 2/2 mice infused with AngII. Examples of en
face aortas with versus without Oil Red O staining are shown in
Figure S1A and S1B, respectively.
AT1b Receptor Deficiency Had No Effect on AngII-
induced AAAs
Following the demonstration of a predominance of AT1b
receptor mRNA in abdominal aortas, we sought to examine the
role of AT1b receptors in AngII-induced AAA formation.
Maximal luminal diameters of supra-renal aortas were determined
in vivo using a high frequency ultrasound at baseline (day 0) and
on day 28 during AngII infusion in LDL receptor 2/2 mice that
were either AT1b receptor +/+ or 2/2. Maximal luminal
diameters significantly increased in both study groups on day 28
during AngII infusion compared to day 0 (Figure 4A; P,0.05).
However, there was no significant difference in luminal diameters
of supra-renal aortas between AT1b receptor +/+ and 2/2 mice
after 28-day infusion of AngII (Figure 4A).
The presence of AAAs were confirmed by measuring maximal
external width of the supra-renal region using an ex vivo method.
There was no significant difference of maximal external width of
supra-renal aortas between AT1b receptor +/+ and 2/2 mice
(Figure 4B). Examples of ultrasound photographs and ex vivo
images of abdominal aortas are shown in Figure 4C.
We also examined histological features of the supra-renal aorta
with Movat’s pentachrome staining. There were no discernible
differences of elastin fibers in supra-renal aortas prior to AngII
infusion (Figure S2A). After AngII infusion, occurrence of focal
elastin disruption in this aortic region was comparable between
AT1b receptor +/+ and 2/2 mice (Figure S2B).
AT1b Receptor Deficiency Had No Effect on AngII-
induced Ascending Aortic Dilation
We have recently reported that chronic AngII infusion also
induces thoracic aortic aneurysms [3,14]. In mice infused with
AngII for 28 days, there was no significant difference in intimal
areas of aortic arches (Figure 5A) and descending thoracic aortas
(Figure 5B) between AT1b receptor +/+ and 2/2 mice.
Figure 2. AngII-induced regional contractions were markedly
reduced by AT1b receptor deficiency. Regional contractility of
aortic rings harvested from the infra-renal aorta of (A) C57BL/6, (B) AT1a
receptor 2/2, or (C) AT1b receptor 2/2 mice. Aortic rings were
contracted during 5-minute incubation with potassium chloride (KCl;
80 mM), 5-hydroxytryptamine (5-HT; 1 mM), or Ang II (1 mM). Contrac-
tions are represented as percent of the maximal contraction achieved
during incubation with KCl (80 mM). Red arrows indicate the return to
normal Krebs–Henseleit solution.
doi:10.1371/journal.pone.0048462.g002
Table 1. Characterization of AT1b receptor +/+ and 2/2
mice infused with AngII.
AT1b receptor genotype +/+ 2/2
N = 16 N = 10
Body weight (g) 24.960.5 23.760.4
SBP (mmHg) 15868 15568
Plasma renin concentration
(ng/ml/30 min)
1.8760.6 1.5660.6
Plasma cholesterol concentration
(mg/dl)
1,690675 1,776664
Body weight, plasma cholesterol and renin concentrations were measured after
termination. SBP was measured during the last week of the study. Values are
represented as mean 6 SEM. There were no significant differences between the
two AT1b receptor genotypes.
doi:10.1371/journal.pone.0048462.t001
AT1b Receptors and Aortic Pathologies
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Discussion
The present study examined the role of AT1b receptors in
aortic tissues in response to AngII. We initially demonstrated the
concordance of the regional abundance of AT1b receptor mRNA
and the presence of functional AT1b receptors in the aorta as the
primary mediator of AngII-induced region-specific contractile
response. Despite the presence of functional AT1b receptors in the
aortic tissue, whole body deficiency of AT1b receptors had no
effect on AngII-induced aortic atherosclerosis and aortic aneurysm
formation in hypercholesterolemic mice.
While both AT1 receptor subtypes are present in aortic tissues,
the abundance of receptor subtype mRNA has only been
characterized in selected aortic regions [30,31]. In the present
study, we demonstrated that both receptor subtypes exhibit
regional differences in mRNA abundances in the aorta. We
confirmed that mRNA of AT1b receptors was significantly more
abundant in the abdominal region compared to the thoracic
region [2,31], and extended previous findings by demonstrating
that the AT1b receptor subtype in the infra-renal region had much
greater abundance than in the supra-renal area. AT1a receptor
mRNA was detected in liver and kidney; however, AT1b receptor
mRNA was absent or negligible in these tissues. Our results are in
agreement with previous studies that AT1a receptors are more
ubiquitously expressed and AT1b receptors are restricted to some
tissues [2,5,8].
AngII is known to promote many physiological and pathological
responses in a region-specific manner in the aorta [2,31–33]. This
may be due to heterogeneous developmental origins of SMCs [34].
Furthermore, it has been demonstrated that contractile responses
to AngII differ in selected regions of the aorta [2,3,8,30,35]. In the
Figure 3. AT1b receptor deficiency had no effect on AngII-
induced atherosclerosis. (A) Percent of atherosclerotic lesion area
was measured on the intimal surface of the aortic arch region (N = 16:
AT1b receptor +/+, and N = 10: AT1b receptor 2/2 mice). (B) Percent of
atherosclerotic lesion area was measured on the intimal surface of the
descending thoracic aorta (N = 16: AT1b receptor +/+, and N = 10: AT1b
receptor 2/2 mice). Inverted triangles represent values from individual
mice, circles represent means, and error bars are SEMs.
doi:10.1371/journal.pone.0048462.g003
Figure 4. AT1b receptor deficiency had no effect on AngII-
induced abdominal aortic dilation in vivo. (A) Maximal luminal
diameters of suprarenal aortas were measured in vivo by ultrasonog-
raphy at baseline (Day 0) and on Day 28 during AngII infusion (N = 16:
AT1b receptor +/+, and N = 10: AT1b receptor 2/2 mice). * denotes
P,0.001 saline versus AngII within AT1b genotypes (two way repeated
measures ANOVA). (B) Maximum width of supra-renal aortas was
measured ex vivo (N = 16: AT1b receptor +/+, and N = 10: AT1b receptor
2/2 mice). Inverted triangles represent individual mice, circles
represent means and error bars are SEM. (C) Examples of ultrasound
images (Day 0 and Day 28) and ex vivo pictures (after termination) of
suprarenal aortas, which represent aortic diameters nearest the mean of
each group.
doi:10.1371/journal.pone.0048462.g004
AT1b Receptors and Aortic Pathologies
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present study, we sought to examine the contractile responses to
AngII in infra-renal aortic tissues in the presence or absence of
AT1a and AT1b receptors. We have noted previously that there
are minimal contractile responses to AngII in ascending and
descending thoracic aortas [3]. AngII promoted contraction of the
infra-renal aorta in C57BL/6 mice. Despite higher abundance of
AT1a receptors in the infra-renal portion of the abdominal aorta,
deletion of AT1a receptors had no effect on contractile responses
to AngII. In contrast, the contractile response to AngII was
diminished in infra-renal aortas from AT1b receptor 2/2 mice.
This effect coincided with the greatest abundance of AT1b
receptor mRNA. Our results are in agreement with a previous
study that indirectly demonstrated AngII-induced contractile
responses being linked to AT1b receptors through the use of an
AT1 receptor antagonist (losartan) in AT1a receptor 2/2 mice
[2]. In another study, AngII-induced contractile responses were
defined in AT1b receptor +/+ and 2/2 mice and demonstrated
that AT1b receptors mediated contraction of abdominal aortas
[11]. The present study demonstrated that the regional specificity
of AngII-induced aortic contractions coincided with the greatest
abundance of AT1b receptor mRNA. However, there are still
quandaries relating to these data. AT1a receptor mRNA was also
most abundant in this region, but this receptor subtype did not
affect AngII-induced contractions in this region. Additionally,
expression of both receptors was detected in the supra-renal aorta,
but this region does not contract in response to AngII stimulation
[3].
Blood pressure is considered an important risk factor for
cardiovascular diseases. A previous study that examined residual
pressor effects of AngII in AT1a receptor 2/2 mice suggested
that AT1b receptors might contribute to pressor effects in the
absence of AT1a receptors [17]. However, it has been demon-
strated previously that whole body deficiency of AT1a receptors
ablates AngII-induced increases of systolic blood pressure [15,29].
The location of AT1a receptors that mediates the increased blood
pressure during AngII infusion has not been defined. Recent
reports provided surprising results that depletion of AT1a
receptors using SM22-promoter driven Cre did not affect AngII-
induced increases in systolic blood pressure [3]. Despite not being
clearly defined, this apparent paradox may be related to the lack of
expression of SM22-driven Cre in the kidney that is a major tissue
controlling AngII-induced hypertension [36,37]. In the present
study, deletion of AT1b receptors had no effect on blood pressure
induced by infusion with AngII. Others have also demonstrated
that AT1b receptor deletion had no effect on AngII-induced
increases in SBP [18]. Overall, despite the requirement of AT1b
receptors for contractile responses to AngII in the infra-renal
aorta, we were unable to demonstrate an effect of AT1b receptors
on blood pressure regulation. As with AT1a receptors, the
contrasting effect of AT1b receptor deficiency on AngII-induced
aortic contraction versus systolic blood pressure presumably
reflects the vascular bed specific effects of AngII.
Hypercholesterolemic mice infused with AngII for 4 weeks
develop aortic atherosclerosis predominantly in the ascending
aortic region [14,15,38,39], while the development of lesions in the
abdominal aortic region is modest unless AngII infusion is
prolonged [13]. Aortas display a gradient of mRNA abundance
for both AT1a and AT1b receptors that was lowest in the
ascending region and highest in the infra-renal region. Although
the ascending aortic region has the lowest abundance for both
AT1a and AT1b receptor mRNA, this is the major site for
initiation and propagation of atherosclerosis [40,41]. Our results
showed that absence of AT1b receptors had no effect on the size of
AngII-induced atherosclerotic lesions in either the aortic arch or
the descending thoracic region in LDL receptor 2/2 mice,
indicating that AT1b receptors do not influence the development
of atherosclerosis. However, despite the low abundance of AT1a
receptor mRNA in the ascending aorta, deficiency of this receptor
ablated AngII-induced atherosclerosis in this region [15]. There-
fore, development of atherosclerosis was not associated with the
regional abundance of mRNA of either AngII type 1 receptor
subtype.
To directly determine the role of AngII stimulation of AT1b
receptors in pathological processes of aortic aneurysm formation,
we infused AngII into AT1b receptor +/+ and 2/2 mice for 28
days. Despite the presence of AT1b receptor mRNA in this region,
deletion of this gene had no effect on AngII-induced AAA
formation. In agreement with previous findings, these results
demonstrate that AT1a receptors are responsible for AngII-
induced AAA formation [15]. AngII infusion promotes pro-
nounced ascending aortic dilation [14] and mRNA of both AT1
receptor subtypes are expressed in this region. However, deletion
of AT1b receptors had no effect on, while whole body deficiency
of AT1a receptors ablated, ascending aortic aneurysms [3].
Therefore, the relative regional mRNA abundance of both AT1
receptor subtypes has no obvious relationship to the location of
AngII-induced aortic pathologies.
Figure 5. AT1b receptor deficiency had no effect on AngII-
induced aortic arch and descending aortic dilation. Intimal area
of (A) aortic arch region and (B) descending thoracic aorta was
measured using an en face method (N = 16: AT1b receptor +/+, and
N = 10: AT1b receptor 2/2 mice). Inverted triangles represent values
from individual mice, circles represent means, and error bars are SEM.
doi:10.1371/journal.pone.0048462.g005
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In summary, there are several major findings in the present
study including AT1b receptors contributing to AngII-induced
aortic contraction that parallels with the mRNA abundance of
AT1b receptors in this region, and AT1b receptors not
contributing to AngII-induced atherosclerosis and aortic aneu-
rysms in either the ascending or abdominal aortic region.
Interestingly, AT1a and AT1b receptors are abundant in the
infra-renal region but exhibit different vascular contractility with
AngII stimulation. These pathophysiological differences may be
due to amino acid differences in the C-terminal region between
the two receptor subtypes, resulting in elicitation of distinct
signaling pathways. Future studies will determine whether relative
variations in the protein sequences of these two receptor subtypes
lead to differential responses to AngII in order to understand the
different modes of action induced by the two receptor subtypes in
AngII-induced vascular diseases.
Supporting Information
Figure S1 Images of en face aortas. (A) Examples of en face
aortas without any staining. Atherosclerotic lesions of which
represent values near the mean of each group. (B) En face aortas
with Oil Red O staining. These aortas are the same as shown in
(A).
(PDF)
Figure S2 Movat’s pentachrome staining of supra-renal
aortic sections. (A) Images of supra-renal aortas from AT1b
receptor +/+ or 2/2 mice prior to AngII infusion (40X). (B)
Images of AAAs from AT1b receptor +/+ or 2/2 mice after 28
days of AngII infusion (40X).
(PDF)
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